Early versus late hormonal therapy for prostate cancer.

Hiroshi Miyamoto, Edward M. Messing

Research output: Contribution to journalReview articlepeer-review

Abstract

Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.

Original languageEnglish (US)
Pages (from-to)188-196
Number of pages9
JournalCurrent urology reports
Volume5
Issue number3
DOIs
StatePublished - Jun 2004

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Early versus late hormonal therapy for prostate cancer.'. Together they form a unique fingerprint.

Cite this